Pluri (NASDAQ:PLUR) Shares Up 3.3% – Here’s What Happened

Pluri Inc. (NASDAQ:PLUR)’s share price traded up 3.3% during trading on Friday . The stock traded as high as $2.0093 and last traded at $1.86. Approximately 37,334 shares changed hands during mid-day trading, a decline of 9% from the average daily volume of 41,117 shares. The stock had previously closed at $1.80.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Pluri from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 7th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Pluri currently has a consensus rating of “Sell”.

Pluri Trading Up 3.3%

The business’s fifty day moving average price is $2.31 and its two-hundred day moving average price is $2.99. The firm has a market cap of $20.07 million, a P/E ratio of -0.41 and a beta of 0.64.

Pluri (NASDAQ:PLUR) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.11. The business had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.66 million.

Institutional Trading of Pluri

A hedge fund recently bought a new position in Pluri stock. Jane Street Group LLC bought a new position in shares of Pluri Inc. (NASDAQ:PLUR) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned 0.14% of Pluri as of its most recent SEC filing. Institutional investors own 16.59% of the company’s stock.

About Pluri

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.